Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 11/29 08:38:01 am
5.722 GBX   -3.02%
11/19SAREUM : Notice of AGM
PU
10/29Appointment of Joint Corporate Broker
PU
10/25SAREUM : Final Results
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/23/2021 11/24/2021 11/25/2021 11/26/2021 11/29/2021 Date
4.35(c) 5.1(c) 5.7(c) 5.9(c) 5.722 Last
139 039 499 57 397 093 45 089 072 39 868 136 14 109 759 Volume
+10.13% +17.24% +11.76% +3.51% -3.02% Change
More quotes
Estimated financial data (e)
Sales 2021 0,17 M 0,23 M 0,23 M
Net income 2021 -1,63 M -2,18 M -2,18 M
Net Debt 2021 - - -
P/E ratio 2021 -118x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -2,15 M -2,87 M -2,87 M
Net Debt 2022 - - -
P/E ratio 2022 -98,3x
Yield 2022 -
Capitalization 199 M 265 M 265 M
Capi. / Sales 2021 1 170x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,5%
More Financials
Company
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in... 
Sector
Biotechnology & Medical Research
Calendar
12/16 | 05:00am
More about the company
All news about SAREUM HOLDINGS PLC
11/19SAREUM : Notice of AGM
PU
10/29Appointment of Joint Corporate Broker
PU
10/25SAREUM : Final Results
PU
10/25Sareum Holdings plc Reports Earnings Results for the Full Year Ended June 30, 2021
CI
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
07/19FTSE 100 Closes Down as Covid Cases Rise
DJ
07/19ALAN JOPE : FTSE 100 Slides as Virus Jitters Weigh
DJ
07/19SAREUM : Subscription to raise ú1,000,000
PU
07/01SAREUM : Completed Covid-19 Research Project Delivers Encouraging Results
PU
06/22SAREUM : to Present at BioTrinity 2021 Conference
PU
More news
News in other languages on SAREUM HOLDINGS PLC
2019SAREUM HOLDINGS PLC : -25% après un placement
More news
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,06 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC143.30%265
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678